Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab

• DOI: 10.1136/jitc-2022-005620
• Publication Date: 2022-12-09T14:15:31Z
• Authors: Raanan Berger; Gal Dinstag; Omer Tirosh; Eyal Schiff; David Kleiner; Kenneth D Aldape; Eytan Ruppin; Tuvik Beker; Razelle Kurzrock
• Keywords: Immune checkpoint; Complete response; CTLA-4

Fibrolamellar carcinoma (FLC) is a rare cancer of the liver that most commonly affects children and young adults. There no clear standard care for disease, whose response to treatment seems be very different from hepatocellular carcinoma. We present case FLC in patient her mid 30s recurred persisted despite resection multiple lines treatment. Following transcriptomic analysis, combination ipilimumab (anti-CTLA4) nivolumab (anti-PD-1) led complete remission, although common biomarkers immune checkpoint blockade were all negative this case. The still remission. Here, combined guided by novel analysis remission after failure several